Scientists Develop Method that Ensures Safe Research on Deadly Flu Viruses
Strategy turns molecules in human lung cells into viral scissors that cut H5N1 bird flu and similar bugs into pieces
A new strategy that dismantles a viral genome in human lung cells will ensure safe research on deadly strains of influenza, say researchers from the Icahn School of Medicine at Mount Sinai.
Details of their “molecular biocontainment” approach, designed to prevent effective transmission of these viruses to humans, are published in Nature Biotechnology.
The strategy they developed and tested will enable healthy molecules in human lung cells to latch on to these viruses and cut the bugs up before they have a chance to infect the human host.
Findings from the study, led by Benjamin tenOever and Adolfo Garcia-Sastre, both Fishberg Professors in the Department of Medicine and Department of Microbiology at Mount Sinai, should resolve concerns that led in 2012 to a worldwide, yearlong voluntary moratorium on research into the deadly H5N1 bird flu.
The ban came after several scientific teams successfully altered the H5N1 viral genome to enable airborne transmission of the bird flu between ferrets — mammals considered a good research model for humans. The public health concern was that altered H5N1 could escape the lab, infect and spread among humans, producing a global pandemic.
“The question last year was whether the risk of altered bird flu escaping laboratories justified the science aimed at understanding the transmission of these viruses. With our method, the possibility of human transmission is no longer a concern,” says Dr. tenOever.
H5N1 normally spreads between poultry and wild birds. It can be transmitted from birds to humans, with difficulty, and has only rarely been passed between people. It is lethal to humans. Since 2003, it has killed 360 people out of 610 people infected.
The researchers say the approach they developed works for all influenza A viruses, which includes H5N1, and potentially with other highly pathogenic RNA viruses, including Ebola and SARS.
Dr. tenOever is known internationally for his work on using microRNAs (miRNAs) — small noncoding RNA molecules that help regulate gene expression — to help the body fight off viral pathogens. He has created a strategy that mimics the system plants use to destroy invading viruses.
“When a plant recognizes viral material, it creates a small inhibitory RNA (siRNA) that latches on to the virus and cleaves it,” says Dr. tenOever. Human cells also have small RNAs in the form of miRNAs, but they are used to maintain cell health — not to fight a virus. Drs. tenOever and Garcia-Sastre — along with scientists from the University of Maryland’s Department of Veterinary Medicine — discovered that if they alter a viral genome by adding a binding site for a miRNA found in human cells, that molecule morphs into a plant-like attacker. It latches on to the virus and destroys it in the same way plant siRNAs do.
In this study, the scientists discovered a specific miRNA (miR-192) that is found in human and mouse lung cells, but not in the lungs of ferrets. They added multiple binding sites for miR-192 on to the H5N1 genome, and demonstrated in mice that, upon contact, lung cells destroyed the virus. They then demonstrated that H5N1 transmission between ferrets was not decreased when altered virus was used. The researchers also showed the approach works with other influenza A viruses.
“It is clear that we can apply this technology to any virus,” Dr. tenOever says. “The only requirements are that we need a miRNA that is present in humans, but not in the model system where we want to study the virus, such as in ferrets. We also need a viral genome that permits insertion of miRNA target sites.”
And once a virus is altered to contain the miRNA target sites, it can replicate ad infinitum for research in laboratories worldwide, Dr. tenOever says. “There is no need to continually go back to the drawing board,” he says.
In January, a handful of scientists in nine nations resumed their research on H5N1, using standard biocontainment procedures. Drs. tenOever and Garcia-Sastre believe that adding this molecular biocontainment strategy to their research should relieve any public concern pertaining to this research.
Study co-authors include Ryan A Langlois, Randy A Albrecht, Jillian S Shapiro, and Mark A Chua from Mount Sinai; and Courtney Finch, Brian Kimble, Troy Sutton, Matthew Angel, Ana Silvia Gonzalez-Reiche, Kemin Xu, and Daniel Perez, from the Department of Veterinary Medicine at the University of Maryland.
The study was predominantly funded by the Center for Research on Influenza Pathogenesis, a National Institute of Allergy and Infectious Diseases–funded Center of Excellence in Influenza Research and Surveillance (HHSN266200700010C).
About The Mount Sinai Medical Center
The Mount Sinai Medical Center encompasses both The Mount Sinai Hospital and Icahn School of Medicine at Mount Sinai. Established in 1968, the Icahn School of Medicine is one of the leading medical schools in the United States, with more than 3,400 faculty in 32 departments and 14 research institutes. It ranks among the top 20 medical schools both in National Institutes of Health (NIH) funding and by U.S. News & World Report. The Mount Sinai Hospital, founded in 1852, is a 1,171-bed tertiary- and quaternary-care teaching facility and one of the nation’s oldest, largest and most-respected voluntary hospitals. The Mount Sinai Hospital is nationally ranked by U.S. News & World Report as one of the top 25 hospitals in 7 specialties based on reputation, safety, and other patient-care factors.
For more information, visit http://www.mountsinai.org.
Find Mount Sinai on:
# # #
About the Mount Sinai Health System
The Mount Sinai Health System is an integrated health system committed to providing distinguished care, conducting transformative research, and advancing biomedical education. Structured around seven hospital campuses and a single medical school, the Health System has an extensive ambulatory network and a range of inpatient and outpatient services—from community-based facilities to tertiary and quaternary care.
The System includes approximately 7,100 primary and specialty care physicians; 12 joint-venture ambulatory surgery centers; more than 140 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. Physicians are affiliated with the renowned Icahn School of Medicine at Mount Sinai, which is ranked among the highest in the nation in National Institutes of Health funding per investigator. The Mount Sinai Hospital is in the "Honor Roll" of best hospitals in America, ranked No. 15 nationally in the 2016-2017 "Best Hospitals" issue of U.S. News & World Report. The Mount Sinai Hospital is also ranked as one of the nation's top 20 hospitals in Geriatrics, Gastroenterology/GI Surgery, Cardiology/Heart Surgery, Diabetes/Endocrinology, Nephrology, Neurology/Neurosurgery, and Ear, Nose & Throat, and is in the top 50 in four other specialties. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 10 nationally for Ophthalmology, while Mount Sinai Beth Israel, Mount Sinai St. Luke's, and Mount Sinai West are ranked regionally. Mount Sinai's Kravis Children's Hospital is ranked in seven out of ten pediatric specialties by U.S. News & World Report in "Best Children's Hospitals."